Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6620 + Avelumab + Carboplatin in PARPi-resistant Ovarian Cancer
NCT03704467Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of berzosertib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by EMD Serono. Primary endpoint: Dose Limiting Toxicities at 3 weeks. Started Mar 2019; status: completed.
02
Drugs
berzosertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03704467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704467.